Peptides vs. GLP-1s for blood sugar: what the evidence says

What did @ayub_ace actually say?

The creator claims a peptide called "MOSI" is "a lot stronger and a lot more efficient with less side effects" than GLP-1 drugs for blood glucose regulation. As evidence, he describes a single client who reportedly dropped from 36 units of insulin per day to 8-10 units after switching from retatrutide to MOSI. He personally recommends "500 micrograms daily" and says it can help people with insulin resistance, PCOS, and metabolic stress. That is a significant clinical claim, built entirely on one anecdote and zero published data.

To be clear about what is being asserted here: a peptide with virtually no published human trial data is being positioned as superior to a class of drugs that have been studied in tens of thousands of patients across multi-year randomized controlled trials. That framing deserves serious scrutiny.

Does the science back this up?

Almost none of it does, and that is not a close call. As of mid-2025, there are no published peer-reviewed human clinical trials on MOSI (also called MOTS-c in research literature) specifically for blood glucose regulation at therapeutic doses in diabetic patients. What exists is early-stage and animal-based.

MOTS-c is a mitochondrial-derived peptide first identified by Lee et al. (2015, Cell Metabolism) that showed insulin-sensitizing effects in mice on a high-fat diet. A subsequent study by Reynolds et al. (2021, Nature Communications) found MOTS-c administration improved glucose tolerance in aged mice and older men in a small pilot, but the human arm involved very few subjects and was not a controlled trial in diabetic patients. The creator is extrapolating from mouse models and a small pilot to "I've found nothing works as fast and as clean as this," which is a substantial leap. GLP-1 receptor agonists, by contrast, are backed by trials like SUSTAIN-6 (Marso et al., 2016, NEJM) involving over 3,000 participants.

What did they get wrong (or right)?

Let us give credit where it is due. The observation that retatrutide can cause elevated heart rate and gastric slowing is accurate. Those are documented side effects in the retatrutide Phase 2 trial (Jastreboff et al., 2023, NEJM), and acknowledging that GLP-1 class drugs carry real side effects is fair commentary. The creator is not wrong that not every patient tolerates these drugs well.

But several things here are clearly wrong or irresponsible. First, a single client case is not evidence of superiority over any drug. That is anecdote, not data. Second, the specific dose recommendation of "500 micrograms daily" has no published clinical basis for human use at this indication. Third, the claim that MOSI can help people with PCOS or general insulin resistance implies a disease-modifying effect that has not been demonstrated in controlled human studies. Presenting this to 1,700 viewers as something you have "found" to work better than established pharmaceuticals, without a single citation, is misleading regardless of the disclaimer in the caption.

What should you actually know?

MOTS-c research is genuinely interesting early science. The mitochondrial signaling pathway it acts on is a legitimate area of metabolic research, and the Lee et al. (2015) findings in rodents were compelling enough to generate real scientific interest. Nobody is saying this peptide is worthless or fake. The problem is the gap between "interesting mouse data plus one small pilot" and "works faster and cleaner than GLP-1s for diabetics."

If you have Type 1 or Type 2 diabetes and are managing insulin, no peptide promoted on TikTok should be changing how you dose. Insulin adjustments in diabetic patients require physician oversight because the risks of getting it wrong, including hypoglycemia, are serious. The creator's framing, that his client reduced insulin dramatically after adding MOSI, without any mention of physician involvement or monitoring, is the kind of content that can genuinely harm people who try to replicate it without medical supervision.

• MOTS-c is a real peptide under legitimate scientific investigation, but human clinical trial data is extremely limited.
• No regulatory body has approved MOTS-c for any medical use.
• If a peptide is changing your insulin requirements, that needs to be managed by a physician, not a TikTok protocol.

The bottom line

The creator is describing a compelling-sounding outcome from a single patient and presenting it as evidence that an unproven peptide beats established drugs. That is not how evidence works. The science on MOTS-c is early and worth watching. It is not mature enough to justify the claims being made here, and some of those claims, particularly around dosing and insulin management, carry real clinical risk for viewers who act on them.